Vaccine Expertise to Protect the World's Health

Vaccines are one of the most effective public health interventions ever developed. They have helped to eradicate smallpox and nearly eradicate polio, and they have significantly reduced the incidence of other diseases, such as measles, mumps, and rubella. Vaccines are also important for protecting people from new and emerging diseases, such as COVID-19.

SR-Vaccines-Hero-1

Let's Drive Your Vaccine Program Forward Together

Southern Research has extensive expertise in vaccine development and testing. SRI has a long history of developing and testing vaccines for a variety of infectious diseases, including influenza, Zika, and COVID-19. Our expertise in vaccine development and testing has made us a valuable partner for government agencies, pharmaceutical companies, and other research institutions.

Our expertise spans a wide range of areas, including:

    • Vaccine antigen discovery and design
    • Vaccine delivery systems
    • Preclinical vaccine testing
    • Clinical trial support
    • Manufacturing and scale-up

We have a proven track record of success in developing and commercializing vaccines. For example, Southern Research played a key role in the development of the following vaccines:

    • MMR vaccine: A combination vaccine that protects against measles, mumps, and rubella.
    • Hepatitis B vaccine: A vaccine that protects against hepatitis B virus (HBV) infection.
    • Varicella vaccine: A vaccine that protects against chickenpox.
    • HPV vaccine: A vaccine that protects against human papillomavirus (HPV) infection.

Southern Research is also working on a number of next-generation vaccines, including vaccines against emerging infectious diseases such as Zika virus, Ebola virus, and Nipah virus. We are also developing new vaccine delivery systems that will make vaccines more effective and accessible to people around the world.

If you are looking for a partner to help you develop and commercialize a new vaccine, Southern Research is the ideal choice. We offer a wide range of services and expertise, and we are committed to helping our clients bring new and innovative vaccines to market.

Contact us today to learn more about how we can help you achieve your vaccine development goals.

mRNA Vaccines

mRNA vaccines are a new type of vaccine that uses messenger RNA (mRNA) to teach the body how to make a protein that triggers an immune response. mRNA vaccines have been used successfully to protect people from COVID-19. They are also being developed to protect people from other diseases, such as malaria, HIV, and cancer.

Learn more about our preclinical services for mRNA vaccines.

Viral Vector Vaccines

Viral vector vaccines are a type of vaccine that uses a modified virus to deliver genetic material from another virus into cells. The modified virus, called the vector virus, is unable to replicate on its own, but it can still deliver the genetic material to cells. Once the genetic material is inside the cell, it is transcribed into mRNA, which is then translated into a protein. The protein then triggers an immune response, including the production of antibodies.

Learn more about our preclinical services for viral vector vaccines.

Live-Attenuated Vaccines

Live-attenuated vaccines are a type of vaccine that uses a weakened or inactive form of a virus or bacteria. The weakened or inactive microbe is still able to stimulate an immune response, but it is not able to cause disease. Live-attenuated vaccines are one of the most effective types of vaccines, and they have been used successfully to prevent diseases such as measles, mumps, rubella, polio, and chickenpox.
Learn more about our preclinical services for live-attenuated vaccines.

Inactivated Adjuvanted Vaccines

Inactivated adjuvanted vaccines are a type of vaccine that uses a killed or inactivated virus or bacteria along with an adjuvant to stimulate an immune response. Adjuvants are substances that are added to vaccines to help them work better. They can help to increase the immune response to the vaccine and make the immunity last longer. Inactivated adjuvanted vaccines are typically used for diseases where a strong immune response is needed, such as influenza, hepatitis B, and human papillomavirus (HPV).

Learn more about our preclinical services for inactivated and inactivated-adjuvanted vaccines.

Submit/Recombinant Protein-Based Vaccines

Recombinant protein-based vaccines are a type of vaccine that uses a recombinant protein to stimulate an immune response. Recombinant proteins are proteins that are produced by combining genes from different organisms. In the case of recombinant protein-based vaccines, the recombinant protein is typically a protein that is found on the surface of a virus or bacteria.

Learn more about our preclinical services for subunit/recombinant protein-based vaccines.

Our Experts

Jennifer Pickens, Ph.D.

Director of Infectious Disease Research

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Scientific Platforms

Omar Moukha-Chafiq, Ph.D.

Director of Chemistry

Partner With Us